Supports expansion of Tevogen’s ExacTcell™ platform toward additional clinical trialsBolsters a financial path to positive cashflow and minimizes dilution WARREN, N.J.,…
Xifaxan is the first and only FDA approved medication for the reduction in risk of OHE recurrence in adultsOvert Hepatic…
Xifaxan is the first and only FDA approved medication for the reduction in risk of OHE recurrence in adultsOvert Hepatic…
The selected clinical research projects will be publicly announced by June 10th, 2024SANTA CLARA, CA / ACCESSWIRE / May 7,…
TARRYTOWN, New York, May 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (OTC:PXMD), a biopharmaceutical company focused on advancing…
SARASOTA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneer in developing innovative intranasal pharmaceuticals…
SIGNA MAGNUSi is a high-performance head-only MR scanner from GE HealthCare that could expand the field of neuroscience, which has…
First quarter revenues of $2.15 billion, up 11% on a Reported and 8% on an Organic1 basisYear-over-year revenue growth in…
REDWOOD CITY, CA / ACCESSWIRE / April 30, 2024 / Biotricity Inc. (NASDAQ:BTCY), a groundbreaking Technology-as-a-Service (TaaS) company committed to…
Highlights ATH434-201 Phase 2 baseline data confirm approach to target biomarkers for slowing disease progressionPresented promising nonclinical data on ATH434…